STOP-UTI

Study on Treatment Outcomes and Prevalence of antimicrobial resistance in Urinary Tract Infections (STOP-UTI)

Uncomplicated lower urinary tract infections (or cystitis) are one of the most common indications for antibiotic treatment in the community. Yet, there is a lack of local Australian data describing both the prevalence and predictors of resistance to first-line antibiotics and the impact of resistance on treatment outcomes. Such information would help inform management guidelines.

The STOP-UTI research project is a prospective cohort study designed to improve our understanding of the optimal management of uncomplicated acute cystitis in the Australian community. We will describe the prevalence and predictors of antibiotic resistance, the use and impact of midstream urine samples, and patient outcomes.

The aims of our research

Specifically, we aim to:

  • Determine the prevalence and predictors of antibiotic resistance
  • Describe the outcomes of patients stratified by empiric antibiotics and susceptibility testing results
  • Explore the role of diagnostic tests in the management of patients with suspected UTIs

Study population

All non-pregnant females aged over 18 years, prescribed an antibiotic for suspected or confirmed acute uncomplicated cystitis in Victorian general practice. Males, pregnant females and patients that are asymptomatic, with a urinary device, or with structural or functional abnormality in the urinary tract are excluded as these UTIs are considered ‘complicated’.

Recruitment process

Participating general practitioners will identify potential participants during standard care and ask if they would be willing to be contacted by a member of our research team. A member of our team will then call the individual to discuss the study and if they wish to take part, we will obtain verbal consent.

Participant involvement

Participants will be asked questions about their treatment and symptoms during the initial call and through a text message each day of their prescription and 28 days after commencing their prescription. If Escherichia coli is identified in the consenting participant’s urine sample sent to Dorevitch Pathology as a part of standard care, the bacteria will undergo further analysis.

Study team

This study is a collaboration between Monash University, Dorevitch Pathology and the University of Melbourne. The coordinating team are:

Ethics: This research is approved by the Alfred Hospital Ethics Committee [HREC/19/Alfred/201].

Further questions: Please contact the study team on stop-uti@monash.edu or 0439 167 207

Thank you for your interest in our study. If you would like to participate or would like to know more, please click here